Merck KGaA MKKGY
34.06 USD +0.85 (+2.56%)
Nov 4, 2026, 3:59 PM EST
33.57 Day range 34.10
23.73 52-week range 34.19
- YTD
- +18.76%
- 1 year
- +32.43%
- Market cap
- 74.04B
- EPS (ttm)
- 1.31
- P/E ratio
- 26.00
- YTD return
- +18.76%
- 1-year return
- +32.43%
- Volume
- 5.34K
- Avg volume
- 89.12K
- Open
- 33.88
- Previous close
- 33.21
- Day's range
- 33.57 – 34.10
- 52-week range
- 23.73 – 34.19
- Earnings date
- Nov 12, 2026
2Y +0.58 (+1.73%)
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate 0.46.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | 0.46 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.47 | 0.26 | -0.21 | -44.68% |
| May 13, 2026 | Mar 31, 2026 | 0.45 | 0.59 | +0.14 | +31.11% |
| Mar 5, 2026 | Dec 31, 2025 | 0.47 | 0.28 | -0.19 | -40.43% |
| Nov 13, 2025 | Sep 30, 2025 | 0.54 | 0.81 | +0.27 | +50.00% |
| Aug 7, 2025 | Jun 30, 2025 | 0.51 | 0.57 | +0.06 | +11.76% |
News
Why Is Silence Therapeutics Stock Skyrocketing Monday? 
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion 
Merck KGaA (OTCMKTS:MKKGY) versus MediciNova (NASDAQ:MNOV) Head-To-Head Contrast 
Merck KGaA (OTCMKTS:MKKGY) Shares Shorted: Short Interest Up 95.4% in September 
Merck KGaA (OTCMKTS:MKKGY) Receives Consensus Rating of “Hold” from Brokerages 
Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal 
Merck KGaA (MKKGY) Q2 2026 Earnings Call Transcript 
Merck KGaA (MKKGY) Misses Q2 Earnings Estimates 
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development 
Merck KGaA (MKKGY) Moves to Strong Buy: Rationale Behind the Upgrade
Your note
Sign in to keep a note on MKKGY — it syncs with the Stock Master app.